Retrospective analyses and meta-analyses have indicated that the risk of pneumonitis increases significantly when CTLA-4 inhibitors are combined with PD-1/PD-L1 blockade, suggesting a potential synergistic effect on immune-mediated lung toxicity (48). Here, CD274 is linked to pneumonitis.